Drug Trial Radar · NCT04295538
Safety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Score (UEMS) In Adult Participants With Acute Traumatic Cervical Spinal Cord Injury (SCI)
Last checked: Nov 19, 2026Latest source record: Feb 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
60
Actual
Start
Sep 6, 2020
Primary completion
Jan 26, 2026
Study completion Jan 26, 2026
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Mar 4, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Acute Spinal Cord Injury (SCI) is a rare injury that leads to permanent neuromotor impairment and sudden disability. Approximately 25,000 people experience cervical SCI in the United States, Europe, and Japan every year. The purpose of this study is to see if elezanumab is safe and assess change in Upper Extremity Motor Score (UEMS) in participants with acute traumatic cervical SCI. Elezanumab is an investigational drug being developed for the treatment of SCI. Elezanumab is a monoclonal antibody, that binds to an inhibitor of neuronal regeneration and neutralizes the inhibitor, thus potentially promoting neuroregeneration. This study is "double-blinded", which means that neither trial participants nor the study doctors will know who will be given which study drug. Study doctors put the participants in 1 of 2 groups, called treatment arms. Each group receives a different treatment. There is a 1 in 3 chance that participants will be assigned to placebo. Participants 18-75 years of age with a SCI will be enrolled. Approximately 54 participants will be enrolled in the study in approximately 49 sites worldwide. Participants will receive intravenous (IV) doses of elezanumab or placebo within 24 hours of injury and every 4 weeks thereafter through Week 48 for a total of 13 doses. There may be a higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the course of the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Conditions
- Spinal Cord Injury (SCI)
Interventions
ElezanumabDrug
Solution for infusion; Intravenous (IV)
PlaceboDrug
Solution for infusion; Intravenous (IV)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Upper Extremity Motor Score (UEMS)Time frame: 52 Weeks
- Number of Participants Experiencing Adverse EventsTime frame: Up to approximately 91 Weeks
Locations
41 sites in 7 countries. Site status is shown where the registry gives one.
University of California Davis Health /ID# 224892
Sacramento, California
Shepherd Center, Inc /ID# 230370
Atlanta, Georgia
Northwestern University Feinberg School of Medicine /ID# 218009
Chicago, Illinois
University of Louisville Hospital /ID# 215948
Louisville, Kentucky
Duplicate_Tufts Medical Center /ID# 225410
Boston, Massachusetts
Brigham & Women's Hospital /ID# 216342
Boston, Massachusetts
Duplicate_Boston University School of Medicine /ID# 218371
Boston, Massachusetts
Beth Israel Deaconess Medical Center /ID# 218149
Boston, Massachusetts
Regents of the University of Michigan /ID# 215890
Ann Arbor, Michigan
Washington University-School of Medicine /ID# 215325
St Louis, Missouri
Hackensack Univ Med Ctr /ID# 215754
Hackensack, New Jersey
Jersey Shore University Medical Center /ID# 218162
Neptune City, New Jersey
Rutgers New Jersey School of Medicine /ID# 216212
Newark, New Jersey
Duplicate_Duke Cancer Center /ID# 216888
Durham, North Carolina
Oregon Medical Research Center /ID# 227371
Portland, Oregon
University of Pennsylvania /ID# 218662
Philadelphia, Pennsylvania
Thomas Jefferson University Hospital /ID# 215460
Philadelphia, Pennsylvania
University of Virginia Health /ID# 218117
Charlottesville, Virginia
Sentara Norfolk General Hospital /ID# 218302
Norfolk, Virginia
Virginia Commonwealth University Medical Center Main Hospital /ID# 217481
Richmond, Virginia
West Virginia University Hospitals /ID# 217344
Morgantown, West Virginia
Wisconsin Medical Center /ID# 215610
Milwaukee, Wisconsin
Royal Adelaide Hospital /ID# 216953
Adelaide, South Australia, Australia
Foothills Medical Centre /ID# 214790
Calgary, Alberta, Canada
QEII - Health Sciences Centre /ID# 215249
Halifax, Nova Scotia, Canada
The Ottawa Hospital Civic Campus /ID# 215270
Ottawa, Ontario, Canada
Toronto Western Hospital /ID# 215214
Toronto, Ontario, Canada
CIUSSS du Nord-de-l'ile-de-Montréal_Hopital du Sacré-Coeur de Montréal /ID# 215210
Montreal, Quebec, Canada
The Chaim Sheba Medical Center /ID# 240917
Ramat Gan, Tel Aviv, Israel
NHO Nagoya Medical Center /ID# 239617
Nagoya, Aichi-ken, Japan
Funabashi Municipal Medical Center /ID# 225599
Funabashi-shi, Chiba, Japan
Japan Organization of Occupational Health and Safety Spinal Injuries Centre /ID# 224141
Iizuka-shi, Fukuoka, Japan
National Hospital Organization Murayama Medical Center /ID# 223492
Musashimurayama-shi, Tokyo, Japan
Ajou University Hospital /ID# 241119
Suwon, Gyeonggido, South Korea
Duplicate_Inha University Hospital /ID# 238890
Junggu, Incheon Gwang Yeogsi, South Korea
Hospital Universitario Vall de Hebron /ID# 217794
Barcelona, Spain
Hospital Universitario 12 de Octubre /ID# 225354
Madrid, Spain
Hospital Universitario Virgen del Rocio /ID# 225692
Seville, Spain
Hospital Nacional de Paraplejicos /ID# 225508
Toledo, Spain
Hospital Universitario y Politecnico La Fe /ID# 217797
Valencia, Spain
Showing 40 of 41 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.